Cargando…

Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age

Dabigatran and warfarin are oral anticoagulant drugs widely used for the prevention of stroke in patients with atrial fibrillation. The objective of this study was to evaluate the interaction between aging and dabigatran- and warfarin-induced gastrointestinal (GI) and nervous system hemorrhage using...

Descripción completa

Detalles Bibliográficos
Autores principales:	ABE, Junko, UMETSU, Ryogo, KATO, Yamato, UEDA, Natsumi, NAKAYAMA, Yoko, SUZUKI, Yukiya, SUZUKI, Toshiyuki, NAGASAWA, Hideko, KINOSADA, Yasutomi, NAKAMURA, Mitsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402434/ https://www.ncbi.nlm.nih.gov/pubmed/25897292 http://dx.doi.org/10.7150/ijms.10703

Ejemplares similares

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events
por: Nakamura, Mitsuhiro, et al.
Publicado: (2015)

Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database
por: Abe, Junko, et al.
Publicado: (2016)

Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
por: Matsui, Toshinobu, et al.
Publicado: (2017)

Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database
por: Abe, Junko, et al.
Publicado: (2017)

Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database
por: Shimada, Kazuyo, et al.
Publicado: (2019)

Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015
por: Horibe, Megumi, et al.
Publicado: (2018)

Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
por: Umetsu, Ryogo, et al.
Publicado: (2021)

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2015)

Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events
por: Sasaoka, Sayaka, et al.
Publicado: (2016)

Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database
por: Hasegawa, Shiori, et al.
Publicado: (2017)

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
por: Reynolds, Shannon L., et al.
Publicado: (2017)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

South African experts comment on FDA approval of dabigatran inatrial fibrillation
por: E, Klug, et al.
Publicado: (2011)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Dabigatran in the Treatment of Warfarin-Induced Skin Necrosis: A New Hope
por: Bakoyiannis, Christos, et al.
Publicado: (2016)

Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review
por: Ganji, Reza, et al.
Publicado: (2016)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
por: Avezum, Alvaro, et al.
Publicado: (2018)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004−2016
por: Motooka, Yumi, et al.
Publicado: (2018)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Effectiveness and safety of dabigatran versus warfarin in “real-world” Japanese patients with atrial fibrillation: A single-center observational study
por: Naganuma, Miyoko, et al.
Publicado: (2017)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Uninterrupted dabigatran is safer than warfarin in patients undergoing ablation for atrial fibrillation
por: Spartalis, Michael, et al.
Publicado: (2017)

Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures
por: Andrade, Marcus Vinicius Santos, et al.
Publicado: (2018)

Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin
por: Moeckel, Gilbert W., et al.
Publicado: (2013)

Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function
por: Fusaro, Maria, et al.
Publicado: (2015)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
por: Kan, Yusuke, et al.
Publicado: (2021)

Dabigatran must be used carefully: literature review and recommendations for management of adverse events
por: Lin, Shan, et al.
Publicado: (2019)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Tamura, Takao, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ott0b35uc9sa13gprj6pq1ai54